Synthetic Biology · eu
Adding a Genetic Switch to CAR-T: Activating Additional Functions After Tumor Recognition
Researchers used synthetic DNA elements to let engineered T cells regulate the expression of added genes in response to stimulation. Fluorescent signals have demonstrated reversible switching, but whether replacing them with therapeutic molecules can deliver both efficacy and safety remains to be verified.
Getting immune cells to recognize cancer cells is one hurdle in cell therapy; getting them to activate additional support functions at the right time when they encounter their targets is another engineering challenge. A team led by the Italian Institute of Technology (IIT) has developed a set of synthetic genetic switches intended to let engineered T cells regulate the activity of added genes according to the biological signals they receive, providing additional control mechanisms for treating solid tumors.
IIT presented the findings on October 14, and the related paper was published in *Nature Communications* on September 16. The research centers on “synthetic promoters”: short stretches of DNA that control gene transcription. According to the research institution, when CAR-T cells recognize tumor antigens and activate intracellular signaling, these elements can convert those signals into expression of added genes.
To observe how the switches work, the team first connected them to genes that produce fluorescent proteins. Fluorescence serves as a trackable readout, allowing researchers to observe gene expression turning on, turning off, and turning on again. This demonstration supports the reversibility of the switches and provides a design foundation for replacing fluorescent proteins with therapeutic molecules in the future.
The toolkit presented in the paper extends beyond a single switch. Researchers selected seven transcription factors from transcriptomic analyses of T-cell activation and designed synthetic promoters that respond to their activity. They first compared expression in HEK293 and Jurkat cells, then introduced some of the designs into primary human CD8-positive T cells. For the promoter responsive to NR4A2, the team further examined its dynamic responses in vitro and in engineered T cells infiltrating tumors in a melanoma xenograft model.
The challenge with these switches involves both whether they can turn on and whether gene expression persists in the absence of stimulation. This background “leakage” could weaken their control. The team therefore incorporated Boolean logic gates and different genetic network designs to reduce basal transcription and widen the gap between the on and off states, making the relationship between intracellular signals and gene output easier to adjust.
However, a gap remains between fluorescence lighting up and a treatment working. The current evidence mainly supports the feasibility of controlling gene expression; it does not establish that the approach has improved patient outcomes or reduced side effects. If therapeutic molecules are connected instead, their production levels, response speed, stability after repeated stimulation, and any inappropriate expression in normal tissues will still need to be verified. Animal models also cannot fully reproduce the human tumor environment.
The value of this work lies in converting the internal activity of T cells into control signals that can be used in engineering designs. The authors have disclosed a patent application covering the MAF and NR4A2 synthetic promoters. The key next step is to connect this control capability to specific therapeutic functions and determine whether the genetic switches can maintain effective output while restricting additional effects to the appropriate times.